Literature DB >> 2444528

Characterization of three monoclonal antibodies against C3 with selective specificities.

K Iida1, K Mitomo, T Fujita, N Tamura.   

Abstract

We raised 15 mouse monoclonal antibodies against human C3 from two separate fusions. Mouse plasmacytoma cells were fused with spleen cells from mice immunized either with a mixture of C3, C3b and C3c, or with a mixture of C3dg and C3d. Three of the 15 monoclonals were characterized in detail. N-7A reacted with native C3 as well as C3b and C3c. Two other monoclonals, C-5G and G-3E, recognized neoantigenic determinants on C3c and C3dg, respectively. In ELISA, C-5G reacted with C3b and C3c but not with native C3 nor with C3dg; and on the other hand G-3E reacted only with C3dg. The selective specificities of these monoclonals were further confirmed in a binding assay to C3 fragments formed on cellular intermediates. C-5G bound exclusively to EC3b, and G-3E bound to EiC3b, EC3dg and EC3d. N-7A bound only very poorly to EC3b. C-5G inhibited both the haemolytic activity of C5 convertase and also the CR1-mediated rosette formation of B-enriched peripheral mononuclear cells with EC3b. G-3E inhibited the CR2-mediated EC3dg-rosette formation of Raji cells. These monoclonals, with selective specificities, can distinguish the state of activation and degradation of the C3 molecule.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444528      PMCID: PMC1454137     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  15 in total

1.  A solid-phase anti-C3 assay for detection of immune complexes in six distinguished forms.

Authors:  K Iida; K Mitomo; T Fujita; N Tamura
Journal:  J Immunol Methods       Date:  1987-04-02       Impact factor: 2.303

2.  Mac-1: a macrophage differentiation antigen identified by monoclonal antibody.

Authors:  T Springer; G Galfré; D S Secher; C Milstein
Journal:  Eur J Immunol       Date:  1979-04       Impact factor: 5.532

3.  Selective inhibition of functional sites of cell-bound C3b by hybridoma-derived antibodies.

Authors:  J D Tamerius; M K Pangburn; H J Müller-Eberhard
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

4.  Three rat monoclonal antibodies to human C3.

Authors:  P J Lachmann; R G Oldroyd; C Milstein; B W Wright
Journal:  Immunology       Date:  1980-11       Impact factor: 7.397

5.  Enharncement of the hemolytic activity of the second component of human complement by oxidation.

Authors:  M J Polley; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

6.  Evidence for presence of an internal thiolester bond in third component of human complement.

Authors:  B F Tack; R A Harrison; J Janatova; M L Thomas; J W Prahl
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

7.  Purification of the human complement control protein C3b inactivator.

Authors:  L G Crossley; R R Porter
Journal:  Biochem J       Date:  1980-10-01       Impact factor: 3.857

8.  Complement receptor is an inhibitor of the complement cascade.

Authors:  K Iida; V Nussenzweig
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

9.  Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

10.  Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus.

Authors:  K Iida; R Mornaghi; V Nussenzweig
Journal:  J Exp Med       Date:  1982-05-01       Impact factor: 14.307

View more
  20 in total

1.  The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci.

Authors:  Lisa A Lewis; Matthew Carter; Sanjay Ram
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

2.  The serum resistance of malaria-infected erythrocytes.

Authors:  Y Kawamoto; K Kojima; Y Hitsumoto; H Okada; V M Holers; A Miyama
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

3.  Molecular remodelling of human CD46 for xenotransplantation: designing a potent complement regulator without measles virus receptor activity.

Authors:  N A Begum; Y Murakami; S Mikata; M Matsumoto; M Hatanaka; S Nagasawa; T Kinoshita; T Seya
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

4.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Authors:  Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

5.  Antibody-independent classical complement pathway activation and homologous C3 deposition in xeroderma pigmentosum cell lines.

Authors:  M Kurita; M Matsumoto; S Tsuji; M Kawakami; Y Suzuki; H Hayashi; K Toyoshima; T Seya
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

6.  ArcA-regulated glycosyltransferase lic2B promotes complement evasion and pathogenesis of nontypeable Haemophilus influenzae.

Authors:  Sandy M S Wong; Frank St Michael; Andrew Cox; Sanjay Ram; Brian J Akerley
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

7.  CD46-independent binding of neisserial type IV pili and the major pilus adhesin, PilC, to human epithelial cells.

Authors:  Marieluise Kirchner; Dagmar Heuer; Thomas F Meyer
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

8.  Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides.

Authors:  B Nilsson; K Nilsson Ekdahl; D Avila; U R Nilsson; J D Lambris
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

9.  Defining targets for complement components C4b and C3b on the pathogenic neisseriae.

Authors:  Lisa A Lewis; Sanjay Ram; Alpana Prasad; Sunita Gulati; Silke Getzlaff; Anna M Blom; Ulrich Vogel; Peter A Rice
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

10.  Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues.

Authors:  M Endoh; M Yamashina; H Ohi; K Funahashi; T Ikuno; T Yasugi; J P Atkinson; H Okada
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.